B-cell Acute Lymphoblastic Leukemia (B-ALL) Clinical Trials

5 recruiting

B-cell Acute Lymphoblastic Leukemia (B-ALL) Trials at a Glance

6 actively recruiting trials for b-cell acute lymphoblastic leukemia (b-all) are listed on ClinicalTrialsFinder across 6 cities in 14 countries. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in Chicago, Duarte, and Bunkyō City. Lead sponsors running b-cell acute lymphoblastic leukemia (b-all) studies include AstraZeneca, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, and Arkansas Children's Hospital Research Institute.

Browse b-cell acute lymphoblastic leukemia (b-all) trials by phase

Treatments under study

About B-cell Acute Lymphoblastic Leukemia (B-ALL) Clinical Trials

Looking for clinical trials for B-cell Acute Lymphoblastic Leukemia (B-ALL)? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new B-cell Acute Lymphoblastic Leukemia (B-ALL) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about B-cell Acute Lymphoblastic Leukemia (B-ALL) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting
Phase 1Phase 2

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

B-cell Acute Lymphoblastic Leukemia (B-ALL)
AstraZeneca163 enrolled80 locationsNCT06137118
Recruiting
Early Phase 1

A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia

Chronic Lymphocytic Leukemia (CLL)B-cell Acute Lymphoblastic Leukemia (B-ALL)B-cell Non-Hodgkin's Lymphoma (B-NHL)
Grit Biotechnology28 enrolled2 locationsNCT07205315
Recruiting
Phase 1Phase 2

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

B-cell Acute Lymphoblastic Leukemia (B-ALL)
AstraZeneca83 enrolled26 locationsNCT07109219
Recruiting
Phase 2Phase 3

NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)

Diffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma ( FL)Relapsed/Refractory Non-Hodgkin Lymphoma+2 more
Health Institutes of Turkey40 enrolled4 locationsNCT07502118
Recruiting

A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab

B-cell Acute Lymphoblastic LeukemiaB-Cell Lymphoblastic LeukemiaB-cell Acute Lymphoblastic Leukemia (B-ALL)+4 more
Arkansas Children's Hospital Research Institute300 enrolled2 locationsNCT07422337
Recruiting
Early Phase 1

JY231 (JY231) Injection for the Treatment of B-cell Acute Lymphoblastic Leukemia (B-ALL)

B-cell Acute Lymphoblastic Leukemia (B-ALL)
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China20 enrolled1 locationNCT06514768